X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8784) 8784
Newsletter (1154) 1154
Book Review (941) 941
Publication (401) 401
Newspaper Article (64) 64
Magazine Article (56) 56
Conference Proceeding (55) 55
Book Chapter (27) 27
Trade Publication Article (16) 16
Dissertation (13) 13
Government Document (3) 3
Transcript (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Journal / eJournal (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
paroxetine (6675) 6675
index medicus (5831) 5831
humans (5080) 5080
male (3632) 3632
female (3230) 3230
psychiatry (3138) 3138
adult (2508) 2508
pharmacology & pharmacy (2250) 2250
middle aged (1958) 1958
paroxetine - therapeutic use (1752) 1752
antidepressants (1616) 1616
fluoxetine (1540) 1540
serotonin uptake inhibitors - therapeutic use (1516) 1516
neurosciences (1513) 1513
depression (1427) 1427
animals (1272) 1272
treatment outcome (1212) 1212
aged (1138) 1138
serotonin (1102) 1102
paroxetine - adverse effects (1090) 1090
double-blind (1024) 1024
serotonin uptake inhibitors - adverse effects (1017) 1017
clinical neurology (958) 958
research (942) 942
depressive disorder - drug therapy (917) 917
sertraline (879) 879
paroxetine - pharmacology (875) 875
rats (840) 840
double-blind method (824) 824
depression, mental (821) 821
antidepressive agents - therapeutic use (792) 792
major depression (786) 786
serotonin uptake inhibitors - pharmacology (749) 749
drug therapy (748) 748
adolescent (700) 700
depressive disorder, major - drug therapy (693) 693
antidepressive agents, second-generation - therapeutic use (674) 674
serotonin reuptake inhibitors (673) 673
efficacy (624) 624
dose-response relationship, drug (619) 619
care and treatment (617) 617
serotonin uptake inhibitors (597) 597
drugs (590) 590
psychiatric status rating scales (584) 584
anxiety (552) 552
major depressive disorder (543) 543
analysis (540) 540
paroxetine - administration & dosage (523) 523
placebo (521) 521
fluvoxamine (516) 516
citalopram (514) 514
serotonin - metabolism (471) 471
abridged index medicus (459) 459
depression - drug therapy (458) 458
antidepressive agents, second-generation - adverse effects (442) 442
reports (441) 441
time factors (441) 441
serotonin uptake inhibitors - administration & dosage (428) 428
antidepressive agents - adverse effects (421) 421
psychology, clinical (421) 421
antidepressant (417) 417
brain (415) 415
medical research (397) 397
drug interactions (394) 394
risk factors (394) 394
imipramine (386) 386
venlafaxine (380) 380
medicine, general & internal (376) 376
drug therapy, combination (361) 361
clinical trials (359) 359
health aspects (358) 358
depressive disorder - psychology (357) 357
fluoxetine - therapeutic use (348) 348
medicine, experimental (347) 347
mental depression (345) 345
brain - metabolism (343) 343
universities and colleges (343) 343
rats, sprague-dawley (341) 341
ssri (337) 337
mice (331) 331
antidepressive agents - pharmacology (329) 329
drug administration schedule (327) 327
serotonin transporter (318) 318
pregnancy (314) 314
dosage and administration (307) 307
panic disorder (307) 307
venlafaxine hydrochloride (299) 299
young adult (299) 299
severity of illness index (292) 292
medicine & public health (291) 291
obsessive-compulsive disorder (291) 291
serotonin plasma membrane transport proteins (290) 290
h-3 paroxetine binding (286) 286
phenols (282) 282
pharmacology (281) 281
disorder (280) 280
psychology (277) 277
pharmaceutical industry (273) 273
comorbidity (270) 270
randomized controlled trials as topic (269) 269
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9590) 9590
German (110) 110
French (100) 100
Spanish (73) 73
Japanese (50) 50
Russian (34) 34
Dutch (25) 25
Italian (25) 25
Chinese (24) 24
Turkish (21) 21
Norwegian (14) 14
Portuguese (14) 14
Polish (12) 12
Czech (10) 10
Korean (7) 7
Swedish (7) 7
Danish (5) 5
Hungarian (3) 3
Hebrew (2) 2
Afrikaans (1) 1
Catalan (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nutrition clinique et metabolisme, ISSN 0985-0562, 12/2014, Volume 28, p. S203
Les corticoides et les progestatifs ont ete utilises comme stimulateurs de l'appetit chez des patients cancereux mais avec un effet relatif et transitoire.... 
Paroxetine
Journal Article
A fatal case of severe serotonin syndrome accompanied by moclobemide and paroxetine overdose, 12/2005
Aim: To present a fatal case of serotonin syndrome accompanied by moclobemide and paroxetine overdose. Case presentation: A 34-year-old married woman was... 
Moclobemide, Paroxetine, Serotonin syndrome
Journal
Nature, ISSN 0028-0836, 04/2016, Volume 532, Issue 7599, pp. 334 - 339
The serotonin transporter (SERT) terminates serotonergic signalling through the sodium-and chloride-dependent reuptake of neurotransmitter into presynaptic... 
HIGH-AFFINITY RECOGNITION | NEUROTRANSMITTER TRANSPORTERS | NOREPINEPHRINE TRANSPORTERS | N-LINKED GLYCOSYLATION | ALLOSTERIC BINDING | BACTERIAL HOMOLOG | MULTIDISCIPLINARY SCIENCES | BINDING-SITE | SELECTIVE RECOGNITION | MEMBRANE-PROTEINS | DOPAMINE TRANSPORTER | Citalopram - pharmacology | Humans | Protein Conformation - drug effects | Crystallography, X-Ray | Dopamine Plasma Membrane Transport Proteins - chemistry | Structure-Activity Relationship | Antidepressive Agents - metabolism | Citalopram - metabolism | Serotonin Plasma Membrane Transport Proteins - chemistry | Extracellular Space - metabolism | Antidepressive Agents - chemistry | Protein Binding - drug effects | Drug Design | Antidepressive Agents - pharmacology | Protein Stability | Allosteric Regulation - drug effects | Ions - chemistry | Serotonin Plasma Membrane Transport Proteins - immunology | Allosteric Site - drug effects | Models, Molecular | Ions - metabolism | Paroxetine - metabolism | Serotonin Plasma Membrane Transport Proteins - metabolism | Citalopram - chemistry | Intracellular Space - metabolism | Serotonin - metabolism | Ligands | Immunoglobulin Fab Fragments - immunology | Paroxetine - pharmacology | Paroxetine - chemistry | Drug metabolism | Paroxetine | Physiological research | Research | Serotonin | Binding sites (Biochemistry) | X rays | Mutation | Antidepressants | Binding sites | Index Medicus
Journal Article
Neurology, ISSN 0028-3878, 04/2012, Volume 78, Issue 16, pp. 1229 - 1236
Objective: To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI)... 
NORTRIPTYLINE | AMITRIPTYLINE | CLINICAL-TRIAL | OUTPATIENTS | GERIATRIC DEPRESSION | PAROXETINE | ISCHEMIC-HEART-DISEASE | MAJOR DEPRESSION | SCALE | FLUOXETINE | CLINICAL NEUROLOGY | Psychiatric Status Rating Scales - statistics & numerical data | Humans | Depressive Disorder - drug therapy | Male | Parkinson Disease - drug therapy | Paroxetine - therapeutic use | Paroxetine - adverse effects | Paroxetine - administration & dosage | Adult | Female | Severity of Illness Index | Adrenergic Uptake Inhibitors - adverse effects | Parkinson Disease - complications | Adrenergic Uptake Inhibitors - therapeutic use | Double-Blind Method | Drug Administration Schedule | Depressive Disorder - diagnosis | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Antidepressive Agents - therapeutic use | Venlafaxine Hydrochloride | Delayed-Action Preparations - adverse effects | Depressive Disorder - complications | Serotonin Uptake Inhibitors - administration & dosage | Adrenergic Uptake Inhibitors - administration & dosage | Cyclohexanols - therapeutic use | Delayed-Action Preparations - therapeutic use | Antidepressive Agents - administration & dosage | Antidepressive Agents - adverse effects | Cyclohexanols - administration & dosage | Parkinson's disease | paroxetine | Neurodegenerative diseases | Antidepressants | Classification | Clinical trials | Depression | Serotonin uptake inhibitors | Venlafaxine | Norepinephrine | Movement disorders | Index Medicus | Abridged Index Medicus | 165 | 239 | 321
Journal Article
Journal Article
Psychoneuroendocrinology, ISSN 0306-4530, 09/2017, Volume 83, pp. 78 - 78
Journal Article
Biophysical Journal, ISSN 0006-3495, 02/2017, Volume 112, Issue 3, pp. 95a - 95a
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2003, Volume 95, Issue 23, pp. 1758 - 1764
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | BREAST-CANCER | MAJOR METABOLITES | ONCOLOGY | 4-HYDROXYLATION | RANDOMIZED CONTROLLED-TRIAL | HUMAN LIVER-MICROSOMES | CYP2D6 ACTIVITY | HOT FLASHES | CYTOCHROME-P450 2D6 | VENLAFAXINE | Cytochrome P-450 CYP2D6 Inhibitors | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Prospective Studies | Cytochrome P-450 Enzyme Inhibitors | Selective Estrogen Receptor Modulators - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - blood | Cytochrome P-450 CYP3A | Humans | Microsomes, Liver - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - pharmacokinetics | Paroxetine - administration & dosage | Paroxetine - blood | Breast Neoplasms - enzymology | Adult | Female | Serotonin Uptake Inhibitors - blood | Chemotherapy, Adjuvant | Antineoplastic Agents, Hormonal - administration & dosage | Enzyme Inhibitors - pharmacology | Tamoxifen - blood | Selective Estrogen Receptor Modulators - administration & dosage | Treatment Outcome | Tamoxifen - pharmacokinetics | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Selective Estrogen Receptor Modulators - blood | Serotonin Uptake Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Aged | Paroxetine | Evaluation | Serotonin uptake inhibitors | Tamoxifen | Clinical trials | Plasma | Breast cancer | Drug therapy | Metabolism | Index Medicus
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 01/2007, Volume 129, Issue 2, pp. 290 - 291
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 07/2003, Volume 86, Issue 1, pp. 13 - 24
The role of serotonin (5-HT) sub(1B) receptors in the mechanism of action of selective serotonin re-uptake inhibitors (SSRI) was studied by using intracerebral... 
paroxetine
Journal Article
Journal Article
Journal Article
Pharmcoepidemiology and Drug Safety, ISSN 1053-8569, 07/2017, Volume 26, Issue 7, pp. 752 - 765
Purpose: Metoprolol and paroxetine/fluoxetine are inevitably co-prescribed because cardiovascular disorders and depression often coexist in the elderly. This... 
CYP2D6 | metoprolol | cytochrome P450 (CYP)‐based drug–drug interactions (DDI) | beta‐blockers | paroxetine/fluoxetine | antidepressants | pharmacoepidemiology | cytochrome P450 (CYP)-based drug–drug interactions (DDI) | beta-blockers | DEPRESSION | INTERACTION ALERTS | HEART-FAILURE | RELEASE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | paroxetine | fluoxetine | PHARMACOKINETICS | PRESCRIPTION | ACUTE MYOCARDIAL-INFARCTION | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | cytochrome P450 (CYP)-based drug-drug interactions (DDI) | ENZYME-INHIBITOR | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Fluoxetine - pharmacokinetics | Humans | Middle Aged | Serotonin Uptake Inhibitors - therapeutic use | Male | Metoprolol - therapeutic use | Metoprolol - administration & dosage | Paroxetine - therapeutic use | Anti-Arrhythmia Agents - therapeutic use | Anti-Arrhythmia Agents - pharmacokinetics | Anti-Arrhythmia Agents - administration & dosage | Paroxetine - administration & dosage | Metoprolol - pharmacokinetics | Drug Interactions | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Cytochrome P-450 CYP2D6 - metabolism | Female | Aged | Fluoxetine - therapeutic use | Elderly people | Cytochrome | Drugs | Therapy | Paroxetine | Metoprolol | Fluoxetine | Cytochrome P450 | Drug interactions | Disorders | Dispensing | Mental depression | Patients | Computer programs | Signaling | Antidepressants | Older people | Software | Drug interaction | Elderly | CYP2D6 protein | Geriatrics | Index Medicus
Journal Article
Journal Article